Navigation Links
Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
Date:5/31/2009

ents (77.0%) were weaned to every-other-day or less dosing of tacrolimus monotherapy. Among 60 recipients with ACR, the incidence of pre-weaning ACR was 8.5% and post-weaning ACR was 27.9%. At this time, >/= 90% of recipients remain steroid-free on tacrolimus monotherapy.

In a similar study report, Dr. Tan and colleagues performed 478 consecutive unselected living donor kidney transplants using alemtuzumab pre-conditioning and tacrolimus monotherapy. Once again, they used a series of clinical tests including ELISA antibody titers, donor-specific antibodies and the ImmuKnow assay beginning 6 months posttransplant and at 2-6 months intervals. Using these data, tacrolimus was weaned whenever possible. These patients were followed for an average of 35.6 (+/-19.7) months.

Recipient survivals at 1, 2, 3, and 4 years were 98.4%, 95.3%, 93.3%, and 90.4%, respectively. Graft survivals at the same time points were 97.1%, 89.6%, 85.2%, and 77.5%, respectively. The mean (+/-SD) creatinine (mg/dL) after 1, 2 and 3 years were 1.42 (+/-0.61), 1.56 (+/-0.96) and 1.53 (+/-0.83), respectively. The mean (+/-SD) GFR (mL/min/1.73m(2)) at these time points were 59.2 (+/-23.6), 55.0 (+/-21.7) and 53.9 (+/-21.7), respectively. The cumulative incidence of ACR after 1, 3, 6, 12, 18, 24, 30, and 36 months were 1.9%, 3.1%, 4.2%, 9.2%, 14.0%, 16.3%, 18.8% and 19.5%, respectively.

Weaning to every-other-day or less dosing of tacrolimus monotherapy was attempted in 41% of patients. Among 397 patients with functional grafts, 82 (20.6%) are on spaced-dose tacrolimus monotherapy. A total of 114 recipients had ACR. The incidence of pre-weaning ACR was 11.7% and post-weaning was 30.1%. At this time, >/= 80.6% of recipients remain steroid-free on tacrolimus monotherapy.

The use of the ImmuKnow assay as described in these studies has not been cleared by the U.S. Food & Drug Administration.

About Im
'/>"/>

SOURCE Cylex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
2. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
3. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
4. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
5. AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors
6. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
7. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
8. DaVita Abstracts Accepted Into National Kidney Foundations 2009 Spring Symposium
9. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
10. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
11. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015   Today: A ... teens nationwide has prompted The Addiction Advisor to ... usage in just 5 minutes. The drug screening ... tools to drug test for thirteen (13) of ... in confidential packaging with instructions and recommendations, parents ...
(Date:6/3/2015)... -- PARI Respiratory Equipment has won a 2015 American Package Design ... the FDA on December 2, is the first co-packaging of ... Nebulizer for patients with cystic fibrosis. ... this unique product offering of nebulized drug and device.  In ... we also wanted to convey that the components suit each ...
(Date:6/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ) ... Future of Pharmaceutical Outsourcing" report to their ... desperate need to develop better drugs with high ... been increasingly utilizing external resources to increase their ... their internal operation. Their outsourcing demands and proportions ...
Breaking Medicine Technology:The Drug Detective Is A Simple Test That Could Save Your Child's Life 2Kitabis Pak Wins American Package Design Award 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... MedShape Solutions, Inc., the industry leader in ... has developed new, larger sizes of its ExoShape ... that simplifies and improves soft tissue graft fixation ... announcement comes after MedShape received the U.S. Food ...
... ActiveCare, Inc. (ACAR.OB) a leader in senior care technology, ... up the rollout of ActiveCare,s ActiveHome products and services ... its, comprehensive ActiveHome Monitoring System.  To guide this market ... his team has extensive experience increasing sales and marketing ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing 2With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing 3
(Date:6/3/2015)... 2015 Johnson & Johnson and its ... to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) filed ... allegedly used to market the antipsychotic drug. Court ... the Arkansas Attorney General moved to dismiss the case ... Risperdal settlement amounts to just a fraction of the ...
(Date:6/3/2015)... 03, 2015 “ Harmony ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... wants to improve some aspect of their life. , A ... for people with difficulties in their life. However, hypnotherapy is ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... 03, 2015 On the heels of a ... industry by 2020 ( click here to review news ... believe Baltimore has the talent to become a ... genetic code and other biological data are collected and analyzed ... “Baltimore contains all the elements of a perfect storm for ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Dr. Steven ... York Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, ... on weekdays to his practice. In most cases, depending on ... of the day they call, they will be seen by ... first priority as a cardiologist is to ensure that people ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2
... ... Institute to identify regions of the dengue virus and Mycobacterium tuberculosis that can be targeted ... Melbourne, ... (NASDAQ Capital Market: CBTE), is pleased to announce that it has been awarded a major ...
... , NASDAQ: CRME ... Pharma Corp. (NASDAQ: CRME / TSX: COM) today ... its directors, officers and employees (each a "restricted person") to ... pursuant to applicable Canadian and U.S. securities laws, including the ...
... Researchers from Boston University School of Medicine (BUSM) have ... of emphysema. The study, which appears on-line in the ... therapeutic genes in lung tissue for a lifetime after only ... most common inherited form of emphysema seen in young people ...
... less clogged in those who nurse infants, study finds, , ... to breast-feed because of the numerous health benefits it offers ... the health of the mothers, hearts later in life. ... that those who had not breast-fed were much more likely ...
... ... rid of their worst menopause and perimenopause symptoms. Don’t Pause contains other natural supplements ... women experience as they age. , ... (PRWEB) December 21, 2009 -- When a woman starts going through ...
... , NEW YORK, Dec. 21 The Center to Advance ... Diane E. Meier, MD , a pioneer in palliative care, has ... of four 2009-2010 Health and Aging Policy Fellows , Dr. ... process at the Federal level. The HELP committee has jurisdiction over ...
Cached Medicine News:Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 2Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 3Health News:Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 2Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 3Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 4Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 5Health News:Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans 6Health News:Researchers discover gene therapy to prevent progression of emphysema 2Health News:Breast-Feeding May Protect a Woman's Heart 2Health News:Breast-Feeding May Protect a Woman's Heart 3Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 2Health News:Women Turn to Natural Menopause Remedies for Safe, Effective Relief 3Health News:Center to Advance Palliative Care Director and MacArthur Recipient, Diane E. Meier, MD, Accepts Fellowship Post With Senate HELP Committee 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: